Skip to main content

RegMedNet is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Topics
    • CAR-T
      • Stem cells
      • Cell therapy
      • Gene therapy
      • Gene editing
    • Cancer
      • Preclinical research
      • Tissue engineering
      • 3D printing
      • Biobanking
    • Clinical trials & funding
      • Manufacturing & scale-up
      • Regulation & policy
      • Industry developments

    Follow us on social media

  • Explore content
    • News
      • The week in cell therapy
      • Spotlights
      • In Focus
      • Interviews
      • Opinion
      • Report
      • App Notes & White Papers
    • eBooks
      • Webinars
      • Podcasts
      • Videos
      • Infographics
      • Partners
      • Events
      • Events news
      • Glossary

    Follow us on social media

  • Our journals
    • Our journals
    • Journal content
    • Journal articles

    Follow us on social media

  • Register
From research to clinical production: scaling iPSC and extracellular vesicle processes 13 days 16 hours 57 mins 1 secs REGISTER NOW

Share your thoughts on immunotherapy in our weekly polls!

8 Jul 2018
Written by RegMedNet
News Spotlight on immunotherapy

Catch up with our weekly polls delving deeper into immunotherapy around the world.

With a new poll every week, we’re finding out more about what you think about immunotherapy. If you missed any, catch up below.

  • Are immunotherapies “regenerative medicines”?
  • What is the biggest challenge in developing an immunotherapy?
  • Will immunotherapies cost less in the future?
  • Do current immunotherapies offer good value in terms of cost per quality adjusted life year?

Top content

  • Cell therapy weekly: investigational AAV-based gene therapy for FSHD completes enrollment
  • Phase I/II Parkinson’s disease cell therapy trial achieves primary endpoint
  • Novel gene therapy harnesses brain’s glymphatic system for targeted delivery
Previous article Next article

  • About
  • Advertising & Sponsorship
  • Expert Panel
  • Permissions & content ownership policy
  • Accessibility
  • Editorial Policies

Contact

Contact Us

Office info

RegMedNet is powered by Taylor & Francis Group

RegMedNet, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 RegMedNet